Mirtazapin Hexal may be available in the countries listed below.
Mirtazapine is reported as an ingredient of Mirtazapin Hexal in the following countries:
International Drug Name Search
Neurexal may be available in the countries listed below.
Gabapentin is reported as an ingredient of Neurexal in the following countries:
International Drug Name Search
Rexicam may be available in the countries listed below.
Piroxicam is reported as an ingredient of Rexicam in the following countries:
International Drug Name Search
Vermitan may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Albendazole is reported as an ingredient of Vermitan in the following countries:
International Drug Name Search
Sandoz Bromazepam may be available in the countries listed below.
Bromazepam is reported as an ingredient of Sandoz Bromazepam in the following countries:
International Drug Name Search
Granisetoron may be available in the countries listed below.
Granisetron is reported as an ingredient of Granisetoron in the following countries:
International Drug Name Search
Methixart may be available in the countries listed below.
Metixene hydrochloride (a derivative of Metixene) is reported as an ingredient of Methixart in the following countries:
International Drug Name Search
Céfaline Hauth may be available in the countries listed below.
Caffeine is reported as an ingredient of Céfaline Hauth in the following countries:
Paracetamol is reported as an ingredient of Céfaline Hauth in the following countries:
International Drug Name Search
Anétholtrithione may be available in the countries listed below.
Anétholtrithione (DCF) is also known as Anetholtrithion (JAN)
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| JAN | Japanese Accepted Name |
Ophtalin may be available in the countries listed below.
Hyaluronic Acid sodium salt (a derivative of Hyaluronic Acid) is reported as an ingredient of Ophtalin in the following countries:
International Drug Name Search
Mydriaticum may be available in the countries listed below.
Tropicamide is reported as an ingredient of Mydriaticum in the following countries:
International Drug Name Search
Methionin Domesco may be available in the countries listed below.
Methionine is reported as an ingredient of Methionin Domesco in the following countries:
International Drug Name Search
Recognan S may be available in the countries listed below.
Citicoline is reported as an ingredient of Recognan S in the following countries:
International Drug Name Search
Metformin Bluefish may be available in the countries listed below.
Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Metformin Bluefish in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
In the US, Desferal (deferoxamine systemic) is a member of the following drug classes: antidotes, chelating agents and is used to treat Iron Poisoning - Acute and Iron Poisoning - Chronic.
US matches:
UK matches:
Deferoxamine is reported as an ingredient of Desferal in the following countries:
Deferoxamine hydrochloride (a derivative of Deferoxamine) is reported as an ingredient of Desferal in the following countries:
Deferoxamine mesilate (a derivative of Deferoxamine) is reported as an ingredient of Desferal in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Quilox may be available in the countries listed below.
Ciprofloxacin is reported as an ingredient of Quilox in the following countries:
International Drug Name Search
Lyosan may be available in the countries listed below.
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Lyosan in the following countries:
International Drug Name Search
Metoclopramida Kern Pharma may be available in the countries listed below.
Metoclopramide hydrochloride (a derivative of Metoclopramide) is reported as an ingredient of Metoclopramida Kern Pharma in the following countries:
International Drug Name Search
Triherpine may be available in the countries listed below.
Trifluridine is reported as an ingredient of Triherpine in the following countries:
International Drug Name Search
Medkiron may be available in the countries listed below.
Medroxyprogesterone 17α-acetate (a derivative of Medroxyprogesterone) is reported as an ingredient of Medkiron in the following countries:
International Drug Name Search
Mannitol Demo may be available in the countries listed below.
Mannitol is reported as an ingredient of Mannitol Demo in the following countries:
International Drug Name Search
AF-TIPA may be available in the countries listed below.
Oxymetazoline is reported as an ingredient of AF-TIPA in the following countries:
International Drug Name Search
Aclarubicine may be available in the countries listed below.
Aclarubicine (DCF) is also known as Aclarubicin (Rec.INN)
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Nuta may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sodium Selenite is reported as an ingredient of Nuta in the following countries:
Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Nuta in the following countries:
International Drug Name Search
Xaclot may be available in the countries listed below.
Ozagrel sodium (a derivative of Ozagrel) is reported as an ingredient of Xaclot in the following countries:
International Drug Name Search
Tobral may be available in the countries listed below.
Tobramycin is reported as an ingredient of Tobral in the following countries:
International Drug Name Search
Cemado may be available in the countries listed below.
Cefamandole nafate (a derivative of Cefamandole) is reported as an ingredient of Cemado in the following countries:
International Drug Name Search
Morphine Hydrochloride may be available in the countries listed below.
Morphine Hydrochloride (BANM) is known as Morphine in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
Methaddict may be available in the countries listed below.
Methadone hydrochloride (a derivative of Methadone) is reported as an ingredient of Methaddict in the following countries:
International Drug Name Search
Flutenal Sali may be available in the countries listed below.
Flupamesone is reported as an ingredient of Flutenal Sali in the following countries:
Salicylic Acid is reported as an ingredient of Flutenal Sali in the following countries:
International Drug Name Search
Mariotton may be available in the countries listed below.
Norfloxacin is reported as an ingredient of Mariotton in the following countries:
International Drug Name Search
Methylfenidaat ratiopharm may be available in the countries listed below.
Methylphenidate hydrochloride (a derivative of Methylphenidate) is reported as an ingredient of Methylfenidaat ratiopharm in the following countries:
International Drug Name Search
Sertraline Teva may be available in the countries listed below.
Sertraline is reported as an ingredient of Sertraline Teva in the following countries:
Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Sertraline Teva in the following countries:
International Drug Name Search
Pinimenthol may be available in the countries listed below.
Levomenthol is reported as an ingredient of Pinimenthol in the following countries:
International Drug Name Search
Prephen may be available in the countries listed below.
Phenol is reported as an ingredient of Prephen in the following countries:
International Drug Name Search
Paxium may be available in the countries listed below.
Chlordiazepoxide is reported as an ingredient of Paxium in the following countries:
International Drug Name Search
Treating steroid-sensitive skin disorders that have a secondary infection caused by bacteria.
Bacitracin/Hydrocortisone/Neomycin/Polymyxin Ointment is a combination of 3 antibiotics and a corticosteroid. The antibiotics kill the bacteria and hydrocortisone reduces inflammation.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Bacitracin/Hydrocortisone/Neomycin/Polymyxin Ointment. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Bacitracin/Hydrocortisone/Neomycin/Polymyxin Ointment. Because little, if any, of Bacitracin/Hydrocortisone/Neomycin/Polymyxin Ointment is absorbed into the blood, the risk of it interacting with another medicine is low.
Ask your health care provider if Bacitracin/Hydrocortisone/Neomycin/Polymyxin Ointment may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Bacitracin/Hydrocortisone/Neomycin/Polymyxin Ointment as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Bacitracin/Hydrocortisone/Neomycin/Polymyxin Ointment.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Burning, dryness, or itching of skin; worsening of condition.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); hearing or kidney problems; second infection.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store Bacitracin/Hydrocortisone/Neomycin/Polymyxin Ointment at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Store away from heat, moisture, and light. Keep Bacitracin/Hydrocortisone/Neomycin/Polymyxin Ointment out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Bacitracin/Hydrocortisone/Neomycin/Polymyxin Ointment. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Metronidazolas L may be available in the countries listed below.
Metronidazole is reported as an ingredient of Metronidazolas L in the following countries:
International Drug Name Search
Bicaprol may be available in the countries listed below.
Bicalutamide is reported as an ingredient of Bicaprol in the following countries:
International Drug Name Search
Karicare Barrier Cream may be available in the countries listed below.
Cetrimide is reported as an ingredient of Karicare Barrier Cream in the following countries:
Dimeticone is reported as an ingredient of Karicare Barrier Cream in the following countries:
International Drug Name Search
Aceralgin may be available in the countries listed below.
Dextropropoxyphene hydrochloride (a derivative of Dextropropoxyphene) is reported as an ingredient of Aceralgin in the following countries:
Paracetamol is reported as an ingredient of Aceralgin in the following countries:
International Drug Name Search
Candacide may be available in the countries listed below.
Nystatin is reported as an ingredient of Candacide in the following countries:
International Drug Name Search
Diacerein Proel may be available in the countries listed below.
Diacerein is reported as an ingredient of Diacerein Proel in the following countries:
International Drug Name Search
Marfarin may be available in the countries listed below.
Warfarin clathrate sodium salt (a derivative of Warfarin) is reported as an ingredient of Marfarin in the following countries:
International Drug Name Search
Cefotaxima Fabra may be available in the countries listed below.
Cefotaxime sodium salt (a derivative of Cefotaxime) is reported as an ingredient of Cefotaxima Fabra in the following countries:
International Drug Name Search
In the US, Medicort is a member of the drug class glucocorticoids and is used to treat Asthma - acute, Bullous Pemphigoid, Dermatitis, Immunosuppression, Inflammatory Conditions, Multiple Sclerosis, Nephrotic Syndrome, Pemphigoid and Pemphigus.
Dexamethasone is reported as an ingredient of Medicort in the following countries:
Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Medicort in the following countries:
Fluticasone propionate (a derivative of Fluticasone) is reported as an ingredient of Medicort in the following countries:
International Drug Name Search
Clotrimazol Bayhealth may be available in the countries listed below.
Clotrimazole is reported as an ingredient of Clotrimazol Bayhealth in the following countries:
International Drug Name Search
Cefaxetil may be available in the countries listed below.
Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Cefaxetil in the following countries:
International Drug Name Search
Rontilona may be available in the countries listed below.
Fluticasone propionate (a derivative of Fluticasone) is reported as an ingredient of Rontilona in the following countries:
International Drug Name Search
Isozid-H may be available in the countries listed below.
Hexetidine is reported as an ingredient of Isozid-H in the following countries:
International Drug Name Search
Generic Name: Torsemide
Class: Loop Diuretics
VA Class: CV702
Chemical Name: N-[[(1-Methylethyl)amino]carbonyl]-4-[(3-methylphenyl) amino]-3-pyridinesulfonamide
Molecular Formula: C16H20N4O3S
CAS Number: 56211-40-6
A sulfonamide, loop-type diuretic and antihypertensive agent.1 a
Management of edema associated with CHF1 4 or hepatic1 or renal1 disease (including chronic renal failure).a
Management of hypertension (alone or in combination with other classes of antihypertensive agents).1 2 3
One of several preferred initial therapies in hypertensive patients with CHF, acute pulmonary edema, or renal disease.2 3
Can be used as monotherapy for initial management of uncomplicated hypertension;1 2 3 a however, thiazide diuretics are preferred by JNC 7.11
The manufacturer states that since oral and IV doses of torsemide are therapeutically equivalent, torsemide dosage is identical for oral or IV administration.1
Most experts state that all patients with symptomatic CHF who have evidence for, or a prior history of, fluid retention generally should receive diuretic therapy in conjunction with moderate sodium restriction (≤3 g of sodium daily), an ACE inhibitor, and usually a β-blocker, with or without a cardiac glycoside.4
Hospitalization of the patient during initiation of therapy is advisable for patients with hepatic cirrhosis and ascites or chronic renal failure.1 a b
Chronic use of any diuretic in hepatic disease has not been adequately studied.1 a
Administer orally, by direct IV injection, or by continuous IV infusion.1
Administer orally without regard to meals.1
For solution and drug compatibility information, see Compatibility under Stability.
IV administration may be used when a rapid onset of diuresis is desired or when oral therapy is not practical.1
If torsemide is administered through an IV line, flush the IV line with 0.9% sodium chloride before and after administration.a
For IV infusion, dilute in 5% dextrose, 0.9% sodium chloride, or 0.45% sodium chloride injection.a
For direct IV injection, administer slowly over a period of 2 minutes.1
Initially, 10–20 mg, given as a single dose.1 Increase as necessary by approximately doubling daily dosage until desired diuresis is attained.1 Single doses exceeding 200 mg not adequately studied.1
Initially, 10–20 mg, given as a single dose.1 Increase as necessary by approximately doubling dosage until desired diuresis is attained.1 Single doses exceeding 200 mg not adequately studied.1
Initially, 5 mg once daily.1 If adequate hypotensive response not attained in 4–6 weeks, may increase dosage to 10 mg once daily.1 If adequate response not observed with 10 mg once daily, an additional antihypertensive agent should be added to antihypertensive therapy.1
Initially, 5 mg once daily.1 If adequate hypotensive response not attained in 4–6 weeks, may increase dosage to 10 mg once daily.1 If adequate response not observed with 10 mg once daily, an additional antihypertensive agent should be added to antihypertensive therapy.1
Maximum of 200 mg as a single dose (daily).1
Maximum of 200 mg as a single dose (daily).1
Maximum of 10 mg once daily.1
Maximum of 10 mg once daily.1
In adults, initially, 20 mg once daily.1 Increase as necessary by approximately doubling dosage until desired diuresis is attained.1 Single doses exceeding 200 mg not adequately studied.1 a
Chronic use in hepatic disease not adequately studied.1
In adults, initially, 5–10 mg once daily, given concomitantly with an aldosterone antagonist or a potassium-sparing diuretic.a Increase as necessary by approximately doubling dosage until desired diuresis is attained.a Single doses exceeding 40 mg not adequately studied.1
Anuria.1
Known hypersensitivity to torsemide or to sulfonylureas.1
Sudden alterations of electrolyte balance in patients with cirrhosis may precipitate hepatic coma; use with caution in patients with hepatic cirrhosis and ascites.1
Therapy in such patients is best initiated in the hospital.1 Use an aldosterone antagonist or potassium-sparing agent concomitantly with torsemide to prevent hypokalemia and metabolic alkalosis in such patients.1
Tinnitus and hearing loss, usually reversible, have been observed following rapid IV injection of other loop diuretics and following oral torsemide administration.1 Administer IV slowly (over 2 minutes); do not exceed 200 mg as a single dose.1
Observe carefully for manifestations of fluid and electrolyte depletion (e.g., dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, nausea, vomiting).1 a
Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in geriatric patients.1 a
Laboratory changes may include altered serum concentrations of sodium, chloride, and potassium; acid-base abnormalities; and increased BUN.1 a If electrolyte imbalance, hypovolemia, or prerenal azotemia develops, torsemide should be discontinued until the abnormality is corrected; treatment then may be restarted at a reduced dosage.1 a
Risk of hypokalemia, especially with brisk diuresis, with inadequate oral electrolyte intake, in those with cirrhosis, or during concomitant use of corticosteroids or ACTH.1 a Risk of arrhythmias secondary to hypokalemia in patients with cardiovascular disease, especially those receiving concomitant therapy with a cardiac glycoside.1 a
Periodically monitor serum potassium and other electrolyte concentrations.1 a
Possible increased blood glucose concentrations; hyperglycemia occurred rarely. 1 a
Small, dose-related, reversible increases in BUN, serum creatinine, and uric acid concentrations reported.1 a Symptomatic gout reported at an incidence similar to placebo.1
Slight alterations in calcium and magnesium concentrations.1 a
Increases in total plasma cholesterol concentrations may occur; usually subside during chronic therapy.1 a
Increases in plasma triglyceride concentrations reported.1 a
In long-term studies, no clinically important differences in lipid profiles compared to baseline.1 a
No clinically important effects on hemoglobin; hematocrit; WBC, erythrocyte, or platelet counts; or serum alkaline phosphatase concentrations.1 a
Category B.1
Not known whether torsemide is distributed into milk.1 Caution if used in nursing women.1
Safety and efficacy not established.1
Renal calcifications reported in severely premature infants with edema secondary to patent ductus arteriosus and hyaline membrane disease receiving another loop diuretic.1 a Increased risk of persistent patent ductus arteriosus in premature neonates with hyaline membrane disease receiving another loop diuretic also has been reported.1 a
No substantial differences in safety and efficacy relative to younger adults.1 a
Seizures reported in patients with acute renal failure receiving higher than recommended dosages of torsemide.1 a
Headache, excessive urination, dizziness, rhinitis, asthenia, diarrhea, ECG abnormality, increased cough.1 a
Drug | Interaction | Comments |
|---|---|---|
Cholestyramine | Decreased absorption of torsemide in animals1 a | Avoid simultaneous administration when used concomitantly1 a |
Digoxin | Increased torsemide AUC1 a | Torsemide dosage adjustment not necessary1 a |
Lithium | Reduced renal clearance of lithium and increased risk of lithium toxicity reported with other diuretics 1 a | Avoid concomitant use or use great caution1 a |
Ototoxic drugs (e.g., aminoglycoside antibiotics, ethacrynic acid) | Possible additive ototoxic effect when ototoxic drugs used concomitantly with other diuretics, especially in those with impaired renal function1 a | |
Probenecid | Reduced secretion of torsemide into proximal tubule and decreased diuretic activity1 a | |
Salicylates (e.g., aspirin, NSAIAs) | Concomitant use of NSAIAs with another loop diuretic (furosemide) occasionally associated with renal dysfunction.1 a Indomethacin may partially inhibit natriuretic effect of torsemide in those with dietary sodium restriction (50 mEq daily) 1 a Concomitant use with high dosages of salicylates may result in salicylate toxicity1 a | |
Spironolactone | Reduced renal clearance of spironolactone1 a | Adjustment of spironolactone or torsemide dosage not necessary1 a |
Bioavailability is approximately 80%.1
Following oral administration, onset of diuresis occurs within 1 hour; maximal effect during the first or second hour.1 a
Following IV administration, onset of diuresis occurs within 10 minutes; maximal effect within 1 hour.1 a
Diuretic effect persists 6–8 hours following oral or IV administration.1 a
Food delays the time to peak plasma concentration following oral dosing but does not affect extent of absorption or diuretic activity.1 a
Following oral administration, peak plasma concentrations achieved within 1 hour.1
Not known whether torsemide is distributed into milk.1 a
>99%.1 a
Hepatic metabolism accounts for approximately 80% of total clearance.1 a Carboxylic acid derivative, the major metabolite, is inactive.1 a
Urinary excretion accounts for approximately 20% of total clearance in patients with normal renal function.1 a Most renal clearance occurs via active secretion of the drug by the proximal tubules into tubular urine.1 a
Approximately 3.5 hours.1 a
In patients with decompensated CHF, hepatic and renal clearance are reduced, resulting in delivery of less drug to the intraluminal site of action and decreased natriuretic effect.1 a Total clearance is about half of that of healthy individuals; half-life and AUC increased.1 a
In patients with renal failure, renal clearance (but not total clearance) is reduced, resulting in delivery of less drug to the intraluminal site of action and decreased natriuretic effect.1 a
In patients with hepatic cirrhosis, renal clearance (but not total clearance) and half-life are increased.1
In geriatric patients, decreased renal clearance.1 a
15–30°C.1 Do not freeze.1 a
15–30°C.1 a Do not freeze.1 a
For information on systemic interactions resulting from concomitant use, see Interactions.
Compatible |
|---|
Dextrose 5% in water |
Sodium chloride 0.45 or 0.9% |
Compatible |
|---|
Milrinone lactate |
Acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the sodium/potassium/chloride carrier system.1
Increases urinary excretion of sodium, chloride, and water without having an important effect on glomerular filtration rate, renal plasma flow, or acid-base balance.1
Risks associated with excessive fluid loss or electrolyte imbalance.1 a
Potential for postural hypotension; importance of rising slowly from a seated position.1
Importance of informing patients with diabetes mellitus that blood glucose concentrations may increase.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Tablets | 5 mg* | Demadex (with povidone; scored) | Roche |
Torsemide Tablets | Apotex, Par, Pliva, Roxane, Teva | |||
10 mg* | Demadex (with povidone; scored) | Roche | ||
Torsemide Tablets | Apotex, Par, Pliva, Roxane, Teva, UDL, | |||
20 mg* | Demadex (with povidone; scored) | Roche | ||
Torsemide Tablets | Apotex, Par, Pliva, Roxane, Teva, UDL | |||
100 mg* | Demadex (with povidone; scored) | Roche | ||
Torsemide Tablets | Apotex, Par, Pliva, Teva | |||
Parenteral | Injection, for IV use | 10 mg/mL | Demadex | Roche |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Demadex 10MG Tablets (MEDA PHARMACEUTICALS): 30/$43.69 or 90/$110.37
Demadex 100MG Tablets (MEDA PHARMACEUTICALS): 30/$160.99 or 90/$455.97
Demadex 20MG Tablets (MEDA PHARMACEUTICALS): 30/$55.99 or 90/$139.97
Torsemide 10MG Tablets (TEVA PHARMACEUTICALS USA): 30/$29.99 or 90/$79.97
Torsemide 100MG Tablets (TEVA PHARMACEUTICALS USA): 30/$89.99 or 90/$249.96
Torsemide 20MG Tablets (TEVA PHARMACEUTICALS USA): 30/$22.99 or 90/$59.98
Torsemide 5MG Tablets (CAMBER PHARMACEUTICALS): 30/$18.99 or 90/$56.97
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions August 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Boehringer Mannheim. Demadex (torsemide) tablets and injection prescribing information. Rockville, MD: 1993 Oct.
2. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health. (NIH publication No. 98-4080.)
3. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. [IDIS 365188] [PubMed 8622249]
4. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9-38A.
5. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. [PubMed 10818056]
6. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. [PubMed 10818055]
7. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. [IDIS 452007] [PubMed 10977801]
8. Associated Press (American Diabetes Association). Diabetics urged: drop blood pressure. Chicago, IL; 2000 Aug 29. Press Release from web site.
9. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-42. [IDIS 490723] [PubMed 12479770]
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. [IDIS 490721] [PubMed 12479763]
11. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) Express. Bethesda, MD: May 14 2003. From NIH website. (http://www.nhlbi.nih.gov/guidelines/hypertension/jncintro.htm). (Also published in JAMA. 2003; 289:2560-72.
a. Roche Pharmaceuticals. Demadex (torsemide) tablets and injection prescribing information. Nutley, NJ: 2003 Apr.
b. AHFS Drug Information 2007. McEvoy GK, ed. Furosemide. American Society of Health-System Pharmacists; 2007: 2690-4.
HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1581.
Prodilantin may be available in the countries listed below.
Fosphenytoin disodium salt (a derivative of Fosphenytoin) is reported as an ingredient of Prodilantin in the following countries:
International Drug Name Search
Calcipotriene (USAN) is also known as Calcipotriol (Rec.INN)
International Drug Name Search
Glossary
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
In the US, Sudafed PE Nasal Decongestant is a member of the following drug classes: decongestants, vasopressors and is used to treat Nasal Congestion.
Phenylephrine hydrochloride (a derivative of Phenylephrine) is reported as an ingredient of Sudafed PE Nasal Decongestant in the following countries:
International Drug Name Search
Zinmax Domesco may be available in the countries listed below.
Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Zinmax Domesco in the following countries:
International Drug Name Search
In the US, Methazolamide (methazolamide systemic) is a member of the drug class carbonic anhydrase inhibitors and is used to treat Glaucoma.
US matches:
Rec.INN
S01EC05
0000554-57-4
C5-H8-N4-O3-S2
236
Carbonic anhydrase inhibitor
Glaucoma treatment
Ophthalmic agent
Acetamide, N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Mirtazapin Arrow may be available in the countries listed below.
Mirtazapine is reported as an ingredient of Mirtazapin Arrow in the following countries:
International Drug Name Search
Estradiol Implants may be available in the countries listed below.
Estradiol is reported as an ingredient of Estradiol Implants in the following countries:
International Drug Name Search
Septadine may be available in the countries listed below.
Povidone-Iodine is reported as an ingredient of Septadine in the following countries:
International Drug Name Search
Sachet Diet CS may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Colistin sulfate (a derivative of Colistin) is reported as an ingredient of Sachet Diet CS in the following countries:
Sulfadimidine is reported as an ingredient of Sachet Diet CS in the following countries:
International Drug Name Search
Meloprol may be available in the countries listed below.
Meloxicam is reported as an ingredient of Meloprol in the following countries:
International Drug Name Search
Ranicodan may be available in the countries listed below.
Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Ranicodan in the following countries:
International Drug Name Search
Generic Name: saxagliptin (SAX a GLIP tin)
Brand Names: Onglyza
Saxagliptin is an oral diabetes medicine that helps control blood sugar levels. It works by regulating the levels of insulin your body produces after eating.
Saxagliptin is for people with type 2 diabetes. Saxagliptin is sometimes used in combination with other diabetes medications, but is not for treating type 1 diabetes.
Saxagliptin may also be used for purposes not listed in this medication guide.
Before you take saxagliptin, tell your doctor if you have kidney disease or if you are on dialysis.
You may take this medicine with or without food. Follow your doctor's instructions.
Saxagliptin is only part of a complete program of treatment that also includes diet, exercise, weight control, and possibly other medications. It is important to use this medicine regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.
To make sure you can safely take saxagliptin, tell your doctor if you have kidney disease or if you are on dialysis.
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Your doctor may occasionally change your dose to make sure you get the best results.
You may take this medicine with or without food. Follow your doctor's instructions.
Check your blood sugar carefully during a time of stress or illness, if you travel, exercise more than usual, drink alcohol, or skip meals. These things can affect your glucose levels and your dose needs may also change.
Your doctor may want you to stop taking saxagliptin for a short time if you become ill, have a fever or infection, or if you have surgery or a medical emergency.
Your blood sugar will need to be checked often, and you may need other blood tests at your doctor's office. Visit your doctor regularly.
Saxagliptin is only part of a complete program of treatment that also includes diet, exercise, weight control, and possibly other medications. It is important to use this medicine regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.
Take the missed dose as soon as you remember (be sure to take the medicine with food if your doctor has instructed you to). Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate;
pain or burning when you urinate;
swelling in your hands, ankles, or feet; or
easy bruising or bleeding.
Less serious side effects may include:
runny or stuffy nose, sore throat, cough;
headache; or
stomach pain.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all other medications you use, especially:
conivaptan (Vaprisol);
diclofenac (Arthrotec, Cataflam, Voltaren, Flector Patch, Solareze);
imatinib (Gleevec);
isoniazid (for treating tuberculosis);
an antibiotic such as clarithromycin (Biaxin), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin, Pediazole), or telithromycin (Ketek);
an antidepressant such as nefazodone;
antifungal medication such as itraconazole (Sporanox), ketoconazole (Nizoral), miconazole (Oravig), or voriconazole (Vfend);
heart or blood pressure medication such as nicardipine (Cardene) or quinidine (Quin-G);
HIV/AIDS medicine such as atazanavir (Reyataz), delavirdine (Rescriptor), fosamprenavir (Lexiva), indinavir (Crixivan), nelfinavir (Viracept), saquinavir (Invirase), or ritonavir (Norvir, Kaletra); or
insulin or an oral diabetes medication such as glipizide (Glucotrol, Metaglip), glimepiride (Amaryl, Avandaryl, Duetact), glyburide (DiaBeta, Micronase, Glucovance), and others.
This list is not complete and other drugs may interact with saxagliptin. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: Onglyza side effects (in more detail)
Progesterone is reported as an ingredient of Progesterone Injection in the following countries:
International Drug Name Search
Rec.INN
N03AA01
0000115-38-8
C13-H14-N2-O3
246
Antiepileptic agent
N-Methyl-5-ethyl-5-phenylbarbituric acid (WHO)
2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-1-methyl-5-phenyl- (USAN)
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Temporarily relieving pain and itching associated with insect bites, minor burns, sunburn, minor skin irritations, minor cuts, scrapes, and rashes due to poison ivy, poison oak, and poison sumac.
Derma-Pax Lotion is an antihistamine. It works by blocking the action of histamine, which reduces the symptoms of an allergic reaction.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Derma-Pax Lotion. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Derma-Pax Lotion. Because little, if any, of Derma-Pax Lotion is absorbed into the blood, the risk of it interacting with another medicine is low.
Ask your health care provider if Derma-Pax Lotion may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Derma-Pax Lotion as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Derma-Pax Lotion.
All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Skin irritation.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Derma-Pax side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Derma-Pax Lotion may be harmful if swallowed. Symptoms after swallowing Derma-Pax Lotion may include confusion, hallucinations, or loss of consciousness.
Store Derma-Pax Lotion at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Store away from heat, moisture, and light. Keep Derma-Pax Lotion out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Derma-Pax Lotion. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
